Biosplice Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Biosplice Therapeutics's estimated annual revenue is currently $10.1M per year.
- Biosplice Therapeutics's estimated revenue per employee is $272,297
- Biosplice Therapeutics's total funding is $799M.
- Biosplice Therapeutics's current valuation is $12B.
Employee Data
- Biosplice Therapeutics has 37 Employees.
- Biosplice Therapeutics grew their employee count by -34% last year.
Biosplice Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Biometrics | Reveal Email/Phone |
4 | VP Corporate Finance | Reveal Email/Phone |
5 | VP Discovery Research | Reveal Email/Phone |
6 | VP, Clinical Development and External Innovation | Reveal Email/Phone |
7 | Executive Director, Portfolio & Programs Management | Reveal Email/Phone |
8 | Associate Director, Statistical Programming | Reveal Email/Phone |
9 | Associate Director, Risk-Based Quality Management (RBQM) | Reveal Email/Phone |
10 | Director, Tumor Biology | Reveal Email/Phone |
Biosplice Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Biosplice Therapeutics?
$799M
Total Funding
37
Number of Employees
$10.1M
Revenue (est)
-34%
Employee Growth %
$12B
Valuation
N/A
Accelerator
Biosplice Therapeutics News
2022-04-20 - GV, Sanofi drive British biotech OMass to $100M series B ...
... Ventures have joined forces to pump $100 million into OMass Therapeutics, ... Biosplice: Once worth $12 billion, Biosplice laid off 41 workers in early...
2022-04-19 - 2 become 1: Caladrius and Cend merge into tumor-focused ...
That's how Caladrius Biosciences and Cend Therapeutics have described their ... Biosplice: Once worth $12 billion, Biosplice laid off 41 workers in early...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10.1M | 37 | 9% | N/A |
#2 | $12.4M | 37 | -14% | N/A |
#3 | $7.1M | 37 | 6% | N/A |
#4 | $3.9M | 37 | -36% | $141M |
#5 | $5.9M | 37 | 19% | N/A |